{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T21:31:46Z","timestamp":1789939906846,"version":"4.0.1"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T00:00:00Z","timestamp":1410825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2015,3,15]]},"abstract":"<jats:p>\n                    This phase II, investigator\u2010initiated, prospective single\u2010arm multinational study (\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                    registration NCT00990860) evaluated sorafenib in combination with doxorubicin\u2010based transarterial chemoembolization (TACE) in patients with intermediate\u2010stage, unresectable hepatocellular carcinoma (HCC). Patients with histologically or clinically diagnosed HCC received TACE with interrupted dosing of sorafenib (sorafenib discontinued for 3 days before and 4\u20137 days after TACE). TACE\/sorafenib cycles were repeated every 6\u20138 weeks. Primary and secondary objectives were, respectively: to evaluate the safety and tolerability of TACE combined with sorafenib, and also their efficacy. The full analysis set comprised 192 patients (mean age 56.1 years). Most were male (87.0%), Eastern Cooperative Oncology Group (ECOG) score 0 (81.8%), Child\u2010Pugh A (91.8%) and Barcelona Clinic Liver Cancer (BCLC) stage B (81.5%); 81.2% had chronic hepatitis B. Combined TACE\/sorafenib was well tolerated, with only 8.1% of patients discontinuing owing to adverse events (AEs). The most common grade \u22653 AEs were palmar\u2010plantar erythrodysesthesia syndrome (15.1%) and decreased platelet count (10.9%). Serious AEs (SAEs) occurred in 52 patients during the study; however, only four were considered related to sorafenib. A mean of 2.7 TACE cycles were administered and 52.6% of patients achieved complete response in target lesions; 16.8% achieved partial response, and 5.8% had progression of disease as their best response, evaluated by modified RECIST. Median progression\u2010free survival and time to progression were 384 and 415 days, respectively, and the estimated 3\u2010year overall survival was 86.1%. This study suggests that the combination of TACE and sorafenib is well tolerated and efficacious; the interrupted sorafenib dosing schedule may have contributed to a considerably lower AE profile than observed in other combination trials.\n                  <\/jats:p>","DOI":"10.1002\/ijc.29126","type":"journal-article","created":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T13:58:27Z","timestamp":1407247107000},"page":"1458-1467","source":"Crossref","is-referenced-by-count":95,"title":["The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in\n                    <scp>A<\/scp>\n                    sian patients with hepatocellular carcinoma: Final results of the\n                    <scp>START<\/scp>\n                    trial"],"prefix":"10.1002","volume":"136","author":[{"given":"Yee","family":"Chao","sequence":"first","affiliation":[{"name":"Division of Chemoradiotherapy Cancer Center, Taipei Veterans General Hospital, School of Medicine, National Yang\u2010Ming University Taipei Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young\u2010Hwa","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine University of Ulsan College of Medicine, Asan Medical Center Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohong","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Liver Disease and Digestive Interventional Radiology Xijing Hospital of Digestive Diseases, 4th Military Medical University Xi'an China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung\u2010Hwan","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Liver Research Institute Seoul National University College of Medicine Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jijin","family":"Yang","sequence":"additional","affiliation":[{"name":"Interventional Division Department of Radiology Changhai Hospital, Second Military Medical University Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology Zhejiang Cancer Hospital Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo\u2010Liang","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Radiology ZheJiang Cancer Hospital HangZhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung Ik","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Medicine Kangbuk Samsung Hospital Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng\u2010Yu","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology Department of Internal Medicine Taichung Veterans General Hospital Taichung Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,9,16]]},"reference":[{"key":"e_1_2_7_2_1","volume-title":"International Agency for Cancer Research","author":"GLOBOCAN","year":"2008"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08649-X"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.05112.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24199"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0027"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-010-9165-7"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2010.00673.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.3350\/kjhep.2009.15.3.391"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-007-9255-7"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/02841850801958890"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v10.i19.2878"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25791"},{"key":"e_1_2_7_14_1","first-page":"1454","article-title":"Clinical significance of plasma D\u2010dimer levels and serum VEGF levels in patients with hepatocellular carcinoma","volume":"51","author":"Tseng CS","year":"2004","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612023393026"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djj069"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12083"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0313"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.05.007"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2368-z"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.1021"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.4_suppl.lba154","article-title":"Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin\u2010eluting beads (DEBDOX) for intermediate\u2010stage hepatocellular carcinoma (HCC): phase II, randomized, double\u2010blind SPACE trial","volume":"30","author":"Lencioni R","year":"2012","journal-title":"J Clin Oncol"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27925"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1247132"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04697.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.01.006"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2009.05784.x"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-S4-05"},{"key":"e_1_2_7_33_1","volume-title":"Presented at the Asian Pacific Association for the Study of Liver (APASL) Liver Week Conference","author":"Han G","year":"2013"},{"key":"e_1_2_7_34_1","unstructured":"NCT01217034. Transcatheter arterial chemoembolization therapy in combination with sorafenib (TACTICS). Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01217034\/(Accessed March 13 2014)."}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.29126","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.29126","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T09:41:13Z","timestamp":1764754873000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.29126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,16]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,3,15]]}},"alternative-id":["10.1002\/ijc.29126"],"URL":"https:\/\/doi.org\/10.1002\/ijc.29126","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,16]]}}}